The Center for Biosimilars® recaps the top stories for the week of February 17, 2020.
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 17, 2020.
Number 5: A new review article discusses the data relevant to inflammatory bowel disease on biosimilars for anti—tumor necrosis factor inhibitors and urges physicians to consider anti-TNF biosimilars for patients with IBD.
Number 4: Which Medicaid plans benefit the most from benefit from the current drug rebate structure and are incentivized to prescribe branded prescriptions? Researchers used the cost issue of follow-on insulin glargine as well as glatiramer acetate to find out.
Number 3: A crossover study comparing autoinjector and prefilled syringe delivery methods of etanercept biosimilar SB4 shows bioequivalent pharmacokinetic parameters and similar safety profiles following a single administration in healthy men.
Number 2: A pharmaceutical industry veteran and consultant for biosimilar makers discusses the ins and outs of the approvals process that cause frustration and unnecessary expense at the recent Specialty Therapies and Biosimilars Congress.
Number 1: Hurdles to a vibrant biosimilar market are not as insurmountable as they appear, according to Center for Biosimilars contributor Steven Lucio, the associate vice president for the Center for Pharmacy Practice Excellence at Vizient.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.